SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
A researcher works in Afrigen's microbiology lab in Cape Town, South Africa on October 5, 2021. (Photo: Kristin Palitza/picture alliance via Getty Images)
'A Big Deal': US, African Scientists to Collaborate on mRNA Vaccine Development
"Scientists are leading the way," said one advocate. "Perhaps political leaders will follow."
Jul 08, 2022
U.S. government scientists on Friday agreed to share technical know-how related to the development of next-generation vaccines and treatments with their counterparts at Afrigen Biologics, a South African drug manufacturer that hosts the first mRNA technology transfer hub established by the World Health Organization and its partners.
"Failure to share technology... imposed a deadly injustice that much of the world will remember for generations."
The National Institutes of Allergy and Infectious Diseases (NIAID) pioneered the use of mRNA and its parent organization, the U.S. National Institutes of Health (NIH), co-invented Moderna's Covid-19 vaccine. Together, NIAID and Afrigen seek to expedite the production of mRNA vaccines--not only to combat the ongoing coronavirus pandemic but also to address other infectious diseases and cancer.
"The pursuit of effective vaccines for human diseases to improve public health is central to the mission of the NIAID Vaccine Research Center," Dr. Richard Koup, acting director of NIAID's VRC, said in a statement. "This collaboration allows us to exchange scientific expertise to further this mission and support Afrigen's globally important research and vaccine discovery efforts."
Zain Rizvi, research director of the Access to Medicines Program at Public Citizen, called the partnership "a big deal." It comes as drugmakers are testing updated Covid-19 vaccines tailored to Omicron and its increasingly evasive subvariants.
Peter Maybarduk, director of Public Citizen's Access to Medicines Program, also applauded the pact, which was announced ahead of a colloquium that brought together leading researchers from NIAID, Afrigen, WHO, and elsewhere.
"These are partnerships the world needs to sustain sharing of the latest science and technology, and to help give countries equitable access to the best medical tools," Maybarduk said in a statement. "Failure to share technology contributed to extreme shortages of Covid vaccines, tests, and treatments, and imposed a deadly injustice that much of the world will remember for generations."
Last April, as starkly unequal access to lifesaving jabs persisted amid a pandemic that has killed millions, WHO and its partners called for the establishment of at least one mRNA technology transfer hub to build capacity in low- and middle-income countries to produce doses locally. Two months later, the first consortium--based at Afrigen in Cape Town--was launched.
By February, scientists at the Afrigen hub were able to replicate the mRNA Covid-19 vaccine co-created by NIH and Moderna despite Big Pharma's best efforts to undermine their work. Instead of supporting the effort, Moderna filed multiple patents in South Africa--after withdrawing or abandoning equivalent ones in several other countries--thus creating legal risks that could jeopardize the hub's output for years to come.
Petro Terblanche, managing director of Afrigen, said Friday that her firm's collaboration with NIAID will enable the WHO-backed mRNA technology transfer hub to "fast-track the end-to-end Good Manufacturing Practices of the first clinical trial material of its Covid-19 vaccine candidate."
Maybarduk echoed Terblanche, saying: "NIAID's expertise and global reputation can help hub partners solve scientific challenges and draw further support from leading governments--and perhaps, eventually, from pharmaceutical corporations."
He also celebrated that researchers at NIAID will be joining "vaccine scientists of global reputation--inspired by and contributing to the hub program and learning from Covid mistakes to build a more equitable future."
As of April, 15 manufacturers in developing countries have been named as "spokes," or recipients of mRNA technology and training from the Afrigen hub. In addition, the WHO has teamed up with South Korea to create a global biomanufacturing teaching facility that will showcase best practices and complement specific trainings developed by researchers involved in the South African project.
Moving forward, "pharmaceutical corporations must provide deep technology transfer," said Maybarduk. "Leading governments must provide funding and logistical support to help establish a distributed network of global manufacturers."
"Scientists are leading the way," he added. "Perhaps political leaders will follow."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Kenny Stancil
Kenny Stancil is senior researcher at the Revolving Door Project and a former staff writer for Common Dreams.
U.S. government scientists on Friday agreed to share technical know-how related to the development of next-generation vaccines and treatments with their counterparts at Afrigen Biologics, a South African drug manufacturer that hosts the first mRNA technology transfer hub established by the World Health Organization and its partners.
"Failure to share technology... imposed a deadly injustice that much of the world will remember for generations."
The National Institutes of Allergy and Infectious Diseases (NIAID) pioneered the use of mRNA and its parent organization, the U.S. National Institutes of Health (NIH), co-invented Moderna's Covid-19 vaccine. Together, NIAID and Afrigen seek to expedite the production of mRNA vaccines--not only to combat the ongoing coronavirus pandemic but also to address other infectious diseases and cancer.
"The pursuit of effective vaccines for human diseases to improve public health is central to the mission of the NIAID Vaccine Research Center," Dr. Richard Koup, acting director of NIAID's VRC, said in a statement. "This collaboration allows us to exchange scientific expertise to further this mission and support Afrigen's globally important research and vaccine discovery efforts."
Zain Rizvi, research director of the Access to Medicines Program at Public Citizen, called the partnership "a big deal." It comes as drugmakers are testing updated Covid-19 vaccines tailored to Omicron and its increasingly evasive subvariants.
Peter Maybarduk, director of Public Citizen's Access to Medicines Program, also applauded the pact, which was announced ahead of a colloquium that brought together leading researchers from NIAID, Afrigen, WHO, and elsewhere.
"These are partnerships the world needs to sustain sharing of the latest science and technology, and to help give countries equitable access to the best medical tools," Maybarduk said in a statement. "Failure to share technology contributed to extreme shortages of Covid vaccines, tests, and treatments, and imposed a deadly injustice that much of the world will remember for generations."
Last April, as starkly unequal access to lifesaving jabs persisted amid a pandemic that has killed millions, WHO and its partners called for the establishment of at least one mRNA technology transfer hub to build capacity in low- and middle-income countries to produce doses locally. Two months later, the first consortium--based at Afrigen in Cape Town--was launched.
By February, scientists at the Afrigen hub were able to replicate the mRNA Covid-19 vaccine co-created by NIH and Moderna despite Big Pharma's best efforts to undermine their work. Instead of supporting the effort, Moderna filed multiple patents in South Africa--after withdrawing or abandoning equivalent ones in several other countries--thus creating legal risks that could jeopardize the hub's output for years to come.
Petro Terblanche, managing director of Afrigen, said Friday that her firm's collaboration with NIAID will enable the WHO-backed mRNA technology transfer hub to "fast-track the end-to-end Good Manufacturing Practices of the first clinical trial material of its Covid-19 vaccine candidate."
Maybarduk echoed Terblanche, saying: "NIAID's expertise and global reputation can help hub partners solve scientific challenges and draw further support from leading governments--and perhaps, eventually, from pharmaceutical corporations."
He also celebrated that researchers at NIAID will be joining "vaccine scientists of global reputation--inspired by and contributing to the hub program and learning from Covid mistakes to build a more equitable future."
As of April, 15 manufacturers in developing countries have been named as "spokes," or recipients of mRNA technology and training from the Afrigen hub. In addition, the WHO has teamed up with South Korea to create a global biomanufacturing teaching facility that will showcase best practices and complement specific trainings developed by researchers involved in the South African project.
Moving forward, "pharmaceutical corporations must provide deep technology transfer," said Maybarduk. "Leading governments must provide funding and logistical support to help establish a distributed network of global manufacturers."
"Scientists are leading the way," he added. "Perhaps political leaders will follow."
Kenny Stancil
Kenny Stancil is senior researcher at the Revolving Door Project and a former staff writer for Common Dreams.
U.S. government scientists on Friday agreed to share technical know-how related to the development of next-generation vaccines and treatments with their counterparts at Afrigen Biologics, a South African drug manufacturer that hosts the first mRNA technology transfer hub established by the World Health Organization and its partners.
"Failure to share technology... imposed a deadly injustice that much of the world will remember for generations."
The National Institutes of Allergy and Infectious Diseases (NIAID) pioneered the use of mRNA and its parent organization, the U.S. National Institutes of Health (NIH), co-invented Moderna's Covid-19 vaccine. Together, NIAID and Afrigen seek to expedite the production of mRNA vaccines--not only to combat the ongoing coronavirus pandemic but also to address other infectious diseases and cancer.
"The pursuit of effective vaccines for human diseases to improve public health is central to the mission of the NIAID Vaccine Research Center," Dr. Richard Koup, acting director of NIAID's VRC, said in a statement. "This collaboration allows us to exchange scientific expertise to further this mission and support Afrigen's globally important research and vaccine discovery efforts."
Zain Rizvi, research director of the Access to Medicines Program at Public Citizen, called the partnership "a big deal." It comes as drugmakers are testing updated Covid-19 vaccines tailored to Omicron and its increasingly evasive subvariants.
Peter Maybarduk, director of Public Citizen's Access to Medicines Program, also applauded the pact, which was announced ahead of a colloquium that brought together leading researchers from NIAID, Afrigen, WHO, and elsewhere.
"These are partnerships the world needs to sustain sharing of the latest science and technology, and to help give countries equitable access to the best medical tools," Maybarduk said in a statement. "Failure to share technology contributed to extreme shortages of Covid vaccines, tests, and treatments, and imposed a deadly injustice that much of the world will remember for generations."
Last April, as starkly unequal access to lifesaving jabs persisted amid a pandemic that has killed millions, WHO and its partners called for the establishment of at least one mRNA technology transfer hub to build capacity in low- and middle-income countries to produce doses locally. Two months later, the first consortium--based at Afrigen in Cape Town--was launched.
By February, scientists at the Afrigen hub were able to replicate the mRNA Covid-19 vaccine co-created by NIH and Moderna despite Big Pharma's best efforts to undermine their work. Instead of supporting the effort, Moderna filed multiple patents in South Africa--after withdrawing or abandoning equivalent ones in several other countries--thus creating legal risks that could jeopardize the hub's output for years to come.
Petro Terblanche, managing director of Afrigen, said Friday that her firm's collaboration with NIAID will enable the WHO-backed mRNA technology transfer hub to "fast-track the end-to-end Good Manufacturing Practices of the first clinical trial material of its Covid-19 vaccine candidate."
Maybarduk echoed Terblanche, saying: "NIAID's expertise and global reputation can help hub partners solve scientific challenges and draw further support from leading governments--and perhaps, eventually, from pharmaceutical corporations."
He also celebrated that researchers at NIAID will be joining "vaccine scientists of global reputation--inspired by and contributing to the hub program and learning from Covid mistakes to build a more equitable future."
As of April, 15 manufacturers in developing countries have been named as "spokes," or recipients of mRNA technology and training from the Afrigen hub. In addition, the WHO has teamed up with South Korea to create a global biomanufacturing teaching facility that will showcase best practices and complement specific trainings developed by researchers involved in the South African project.
Moving forward, "pharmaceutical corporations must provide deep technology transfer," said Maybarduk. "Leading governments must provide funding and logistical support to help establish a distributed network of global manufacturers."
"Scientists are leading the way," he added. "Perhaps political leaders will follow."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.